Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.

Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.

Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Loupy A, Halloran PF, Dragun D.

Kidney Int. 2019 Jul;96(1):189-201. doi: 10.1016/j.kint.2019.01.030. Epub 2019 Mar 15.

PMID:
31005275
2.

The therapeutic challenge of late antibody-mediated kidney allograft rejection.

Böhmig GA, Eskandary F, Doberer K, Halloran PF.

Transpl Int. 2019 Apr 7. doi: 10.1111/tri.13436. [Epub ahead of print] Review.

PMID:
30955215
3.

Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers.

Reeve J, Böhmig GA, Eskandary F, Einecke G, Gupta G, Madill-Thomsen K, Mackova M, Halloran PF; INTERCOMEX MMDx-Kidney Study Group.

Am J Transplant. 2019 Mar 13. doi: 10.1111/ajt.15351. [Epub ahead of print]

PMID:
30868758
4.

An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms.

Parkes MD, Aliabadi AZ, Cadeiras M, Crespo-Leiro MG, Deng M, Depasquale EC, Goekler J, Kim DH, Kobashigawa J, Loupy A, Macdonald P, Potena L, Zuckermann A, Halloran PF.

J Heart Lung Transplant. 2019 Jun;38(6):636-646. doi: 10.1016/j.healun.2019.01.1318. Epub 2019 Feb 6.

PMID:
30795962
5.

Molecular assessment of rejection and injury in lung transplant biopsies.

Halloran KM, Parkes MD, Chang J, Timofte IL, Snell GI, Westall GP, Hachem R, Kreisel D, Trulock E, Roux A, Juvet S, Keshavjee S, Jaksch P, Klepetko W, Halloran PF.

J Heart Lung Transplant. 2019 May;38(5):504-513. doi: 10.1016/j.healun.2019.01.1317. Epub 2019 Feb 6.

PMID:
30773443
6.

Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.

Eskandary F, Dürr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, Wahrmann M, Regele H, Spittler A, Lachmann N, Firbas C, Mühlbacher J, Bond G, Halloran PF, Chong E, Jilma B, Böhmig GA.

Trials. 2019 Jan 11;20(1):37. doi: 10.1186/s13063-018-3158-6.

7.

Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas.

Halloran PF, Matas A, Kasiske BL, Madill-Thomsen KS, Mackova M, Famulski KS.

Am J Transplant. 2019 May;19(5):1356-1370. doi: 10.1111/ajt.15178. Epub 2018 Dec 13.

PMID:
30417539
8.

Exploring the cardiac response to injury in heart transplant biopsies.

Halloran PF, Reeve J, Aliabadi AZ, Cadeiras M, Crespo-Leiro MG, Deng M, Depasquale EC, Goekler J, Jouven X, Kim DH, Kobashigawa J, Loupy A, Macdonald P, Potena L, Zuckermann A, Parkes MD.

JCI Insight. 2018 Oct 18;3(20). pii: 123674. doi: 10.1172/jci.insight.123674.

9.

Belatacept rescue for delayed kidney allograft function in a patient with previous combined heart-liver transplant.

Kumar D, Yakubu I, Cooke RH, Halloran PF, Gupta G.

Am J Transplant. 2018 Oct;18(10):2613-2614. doi: 10.1111/ajt.15003. Epub 2018 Aug 3. No abstract available.

PMID:
29981184
10.

Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR).

Roux A, Levine DJ, Zeevi A, Hachem R, Halloran K, Halloran PF, Gibault L, Taupin JL, Neil DAH, Loupy A, Adam BA, Mengel M, Hwang DM, Calabrese F, Berry G, Pavlisko EN.

Am J Transplant. 2019 Jan;19(1):21-31. doi: 10.1111/ajt.14990. Epub 2018 Aug 1.

PMID:
29956477
11.

Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation.

Arnold ML, Kainz A, Hidalgo LG, Eskandary F, Kozakowski N, Wahrmann M, Haslacher H, Oberbauer R, Heilos A, Spriewald BM, Halloran PF, Böhmig GA.

Am J Transplant. 2018 Sep;18(9):2261-2273. doi: 10.1111/ajt.14710. Epub 2018 Mar 30.

PMID:
29478298
12.

Letter to AJT editor re: Nankivell et al.

Famulski KS, Halloran PF.

Am J Transplant. 2018 Mar;18(3):765-766. doi: 10.1111/ajt.14653. Epub 2018 Feb 3. No abstract available.

13.

The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, van Huyen JPD, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M.

Am J Transplant. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21.

14.

A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.

Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Böhmig GA.

J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14.

15.

Review: The transcripts associated with organ allograft rejection.

Halloran PF, Venner JM, Madill-Thomsen KS, Einecke G, Parkes MD, Hidalgo LG, Famulski KS.

Am J Transplant. 2018 Apr;18(4):785-795. doi: 10.1111/ajt.14600. Epub 2017 Dec 23. Review.

16.

Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.

Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A.

J Am Soc Nephrol. 2018 Feb;29(2):620-635. doi: 10.1681/ASN.2017050589. Epub 2017 Oct 17.

17.

A molecular biopsy test based on arteriolar under-hyalinosis reflects increased probability of rejection related to under-immunosuppression.

Einecke G, Reeve J, Halloran PF.

Am J Transplant. 2018 Apr;18(4):821-831. doi: 10.1111/ajt.14532. Epub 2017 Nov 10.

18.

Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.

Eskandary F, Jilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC, Halloran PF, Böhmig GA.

Am J Transplant. 2018 Apr;18(4):916-926. doi: 10.1111/ajt.14528. Epub 2017 Oct 31.

19.

Response by Loupy et al to Letters Regarding Article, "Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection".

Loupy A, Hidalgo L, Duong JP, Bruneval P, Jouven X, Halloran PF.

Circulation. 2017 Aug 15;136(7):698-699. doi: 10.1161/CIRCULATIONAHA.117.029146. No abstract available.

PMID:
28808152
20.

Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic (MMDx) System.

Halloran PF, Potena L, Van Huyen JD, Bruneval P, Leone O, Kim DH, Jouven X, Reeve J, Loupy A.

J Heart Lung Transplant. 2017 Nov;36(11):1192-1200. doi: 10.1016/j.healun.2017.05.029. Epub 2017 May 29.

PMID:
28662985
21.

Mechanistic Sharing Between NK Cells in ABMR and Effector T Cells in TCMR.

Parkes MD, Halloran PF, Hidalgo LG.

Am J Transplant. 2018 Jan;18(1):63-73. doi: 10.1111/ajt.14410. Epub 2017 Aug 14.

22.

Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.

Reeve J, Böhmig GA, Eskandary F, Einecke G, Lefaucheur C, Loupy A, Halloran PF; MMDx-Kidney study group.

JCI Insight. 2017 Jun 15;2(12). pii: 94197. doi: 10.1172/jci.insight.94197. eCollection 2017 Jun 15.

23.

Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study.

Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, Bromberg J, Einecke G, Eskandary F, Gosset C, Duong Van Huyen JP, Gupta G, Lefaucheur C, Malone A, Mannon RB, Seron D, Sellares J, Weir M, Loupy A.

Am J Transplant. 2017 Nov;17(11):2851-2862. doi: 10.1111/ajt.14329. Epub 2017 May 30.

24.

Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.

Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, Jouven X, Glotz D, Legendre C, Lefaucheur C, Halloran PF.

J Am Soc Nephrol. 2017 Jun;28(6):1912-1923. doi: 10.1681/ASN.2016070797. Epub 2017 Mar 2.

25.

The Effect of Cortex/Medulla Proportions on Molecular Diagnoses in Kidney Transplant Biopsies: Rejection and Injury Can Be Assessed in Medulla.

Madill-Thomsen KS, Wiggins RC, Eskandary F, Böhmig GA, Halloran PF.

Am J Transplant. 2017 Aug;17(8):2117-2128. doi: 10.1111/ajt.14233. Epub 2017 Mar 23.

26.

Biopsy transcriptome expression profiling: proper validation is key.

Reeve J, Halloran PF.

Lancet. 2017 Feb 11;389(10069):600-601. doi: 10.1016/S0140-6736(17)30282-9. No abstract available.

PMID:
28195055
27.

Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection.

Loupy A, Duong Van Huyen JP, Hidalgo L, Reeve J, Racapé M, Aubert O, Venner JM, Falmuski K, Bories MC, Beuscart T, Guillemain R, François A, Pattier S, Toquet C, Gay A, Rouvier P, Varnous S, Leprince P, Empana JP, Lefaucheur C, Bruneval P, Jouven X, Halloran PF.

Circulation. 2017 Mar 7;135(10):917-935. doi: 10.1161/CIRCULATIONAHA.116.022907. Epub 2017 Feb 1.

PMID:
28148598
28.

Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation.

Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M.

Transplantation. 2017 Feb;101 Suppl 2S:S1-S41. doi: 10.1097/TP.0000000000001563. No abstract available.

PMID:
28125449
29.

Comprehensive Analysis of Transcript Changes Associated With Allograft Rejection: Combining Universal and Selective Features.

Halloran PF, Venner JM, Famulski KS.

Am J Transplant. 2017 Jul;17(7):1754-1769. doi: 10.1111/ajt.14200. Epub 2017 Feb 25.

30.

Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection.

Parkes MD, Halloran PF, Hidalgo LG.

Transplantation. 2017 Apr;101(4):e102-e111. doi: 10.1097/TP.0000000000001586.

PMID:
27906829
31.

Hyalinosis Lesions in Renal Transplant Biopsies: Time-Dependent Complexity of Interpretation.

Einecke G, Reeve J, Halloran PF.

Am J Transplant. 2017 May;17(5):1346-1357. doi: 10.1111/ajt.14136. Epub 2017 Jan 3.

32.

Relationships among injury, fibrosis, and time in human kidney transplants.

Venner JM, Famulski KS, Reeve J, Chang J, Halloran PF.

JCI Insight. 2016 Jan 21;1(1):e85323. doi: 10.1172/jci.insight.85323.

33.

Molecular assessment of disease states in kidney transplant biopsy samples.

Halloran PF, Famulski KS, Reeve J.

Nat Rev Nephrol. 2016 Sep;12(9):534-48. doi: 10.1038/nrneph.2016.85. Epub 2016 Jun 27. Review.

PMID:
27345248
34.

A Probabilistic Approach to Histologic Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Biopsies.

Halloran PF, Famulski KS, Chang J.

Am J Transplant. 2017 Jan;17(1):129-139. doi: 10.1111/ajt.13934. Epub 2016 Aug 3.

35.

Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.

Eskandary F, Bond G, Kozakowski N, Regele H, Marinova L, Wahrmann M, Kikić Ž, Haslacher H, Rasoul-Rockenschaub S, Kaltenecker CC, König F, Hidalgo LG, Oberbauer R, Halloran PF, Böhmig GA.

Transplantation. 2017 Mar;101(3):631-641. doi: 10.1097/TP.0000000000001195.

PMID:
27120452
36.

Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants.

Halloran PF, Merino Lopez M, Barreto Pereira A.

Am J Transplant. 2016 Mar;16(3):908-20. doi: 10.1111/ajt.13551. Epub 2016 Jan 6.

37.

Using Molecular Phenotyping to Guide Improvements in the Histologic Diagnosis of T Cell-Mediated Rejection.

Reeve J, Chang J, Salazar ID, Lopez MM, Halloran PF.

Am J Transplant. 2016 Apr;16(4):1183-92. doi: 10.1111/ajt.13572. Epub 2016 Jan 5.

38.

Determinants of ventricular arrhythmias in human explanted hearts with dilated cardiomyopathy.

Parajuli N, Valtuille L, Basu R, Famulski KS, Halloran PF, Sergi C, Oudit GY.

Eur J Clin Invest. 2015 Dec;45(12):1286-96. doi: 10.1111/eci.12549. Epub 2015 Nov 18.

PMID:
26444674
39.

The molecular phenotypes of rejection in kidney transplant biopsies.

Halloran PF, Famulski K, Reeve J.

Curr Opin Organ Transplant. 2015 Jun;20(3):359-67. doi: 10.1097/MOT.0000000000000193.

PMID:
25944235
40.

Reassessing the Significance of Intimal Arteritis in Kidney Transplant Biopsy Specimens.

Salazar ID, Merino López M, Chang J, Halloran PF.

J Am Soc Nephrol. 2015 Dec;26(12):3190-8. doi: 10.1681/ASN.2014111064. Epub 2015 Apr 27.

41.

The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors.

Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF.

Am J Transplant. 2015 May;15(5):1336-48. doi: 10.1111/ajt.13115. Epub 2015 Mar 17.

42.

Common errors in the implementation and interpretation of microarray studies.

Reeve J, Halloran PF, Kaplan B.

Transplantation. 2015 Mar;99(3):470-5. doi: 10.1097/TP.0000000000000691.

PMID:
25695786
43.

Molecular patterns in human ulcerative colitis and correlation with response to infliximab.

Halloran B, Chang J, Shih DQ, McGovern D, Famulski K, Evaschesen C, Fedorak RN, Thiesen A, Targan S, Halloran PF.

Inflamm Bowel Dis. 2014 Dec;20(12):2353-63. doi: 10.1097/MIB.0000000000000239.

44.

Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients.

Halloran PF, Chang J, Famulski K, Hidalgo LG, Salazar ID, Merino Lopez M, Matas A, Picton M, de Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J.

J Am Soc Nephrol. 2015 Jul;26(7):1711-20. doi: 10.1681/ASN.2014060588. Epub 2014 Nov 6.

45.

Molecular landscape of T cell-mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands.

Venner JM, Famulski KS, Badr D, Hidalgo LG, Chang J, Halloran PF.

Am J Transplant. 2014 Nov;14(11):2565-76. doi: 10.1111/ajt.12946. Epub 2014 Sep 12.

46.

Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection.

Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T, Verine J, Aubert O, Dubleumortier S, Duong van Huyen JP, Jouven X, Glotz D, Legendre C, Halloran PF.

J Am Soc Nephrol. 2014 Oct;25(10):2267-77. doi: 10.1681/ASN.2013111149. Epub 2014 Apr 3.

47.

The role of donor-specific HLA alloantibodies in liver transplantation.

O'Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, Knechtle SJ, McDiarmid SV, Shaked A, Terasaki PI, Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle ES, Zachary AA, Klintmalm GB.

Am J Transplant. 2014 Apr;14(4):779-87. doi: 10.1111/ajt.12667. Epub 2014 Mar 1.

48.

Transplantation: Autoantibodies-epiphenomena or biological clues.

Halloran PF.

Nat Rev Nephrol. 2013 Dec;9(12):705-6. doi: 10.1038/nrneph.2013.221. Epub 2013 Oct 22.

PMID:
24145327
49.

Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM).

Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J.

Am J Transplant. 2013 Nov;13(11):2865-74. doi: 10.1111/ajt.12465. Epub 2013 Oct 3.

50.

Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies.

Halloran PF, Reeve JP, Pereira AB, Hidalgo LG, Famulski KS.

Kidney Int. 2014 Feb;85(2):258-64. doi: 10.1038/ki.2013.300. Epub 2013 Aug 21. Review.

Supplemental Content

Loading ...
Support Center